Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study

被引：0

作者：

Satoshi Tamada

Chihiro Kondoh

Nobuaki Matsubara

Ryuichi Mizuno

Go Kimura

Satoshi Anai

Yoshihiko Tomita

Masafumi Oyama

Naoya Masumori

Takahiro Kojima

Hiroaki Matsumoto

Mei Chen

Mengran Li

Kenji Matsuda

Yoshinobu Tanaka

Brian I. Rini

Hirotsugu Uemura

机构：

[1] Bell Land General Hospital,

[2] Toranomon Hospital,undefined

[3] National Cancer Center Hospital East,undefined

[4] Keio University Hospital,undefined

[5] Nippon Medical School Hospital,undefined

[6] Nara Medical University Hospital,undefined

[7] Niigata University Medical & Dental Hospital,undefined

[8] Saitama Medical University International Medical Center,undefined

[9] Sapporo Medical University,undefined

[10] University of Tsukuba,undefined

[11] Aichi Cancer Center,undefined

[12] Yamaguchi University,undefined

[13] Merck & Co.,undefined

[14] Inc.,undefined

[15] MSD K.K.,undefined

[16] Cleveland Clinic Taussig Cancer Institute,undefined

[17] Vanderbilt-Ingram Cancer Center,undefined

[18] Kindai University,undefined

来源：

International Journal of Clinical Oncology | 2022年 / 27卷

关键词：

Metastatic renal cell carcinoma; Axitinib; PD-1 checkpoint inhibitor; Pembrolizumab; Vascular endothelial growth factor receptor inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：154 / 164

页数：10

共 30 条

[1] Hsieh JJ(2017)Renal cell carcinoma Nat Rev Dis Primers 3 17009-626
[2] Purdue MP(2015)Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy Cancer Sci 106 618-1828
[3] Signoretti S(2019)Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma Cancer Sci 110 1820-2270
[4] Shinohara N(2016)Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration Clin Cancer Res 22 2261-1028
[5] Obara W(2021)Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma J Clin Oncol 39 1020-1039
[6] Tatsugami K(2021)Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma J Clin Oncol 39 1029-1127
[7] Mikami S(2019)Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma N Engl J Med 380 1116-1573
[8] Mizuno R(2020)Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial Lanc Oncol 21 1563-19
[9] Kondo T(2020)Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up Jpn J Clin Oncol 50 12-923
[10] Ock CY(2020)Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 Cancer Sci 111 907-undefined

← 1 2 3 →